GW Pharmaceuticals to file Sativex in Europe for spasticity in MS
This article was originally published in Scrip
GW Pharmaceuticals is to file its cannabis extract CB1 agonist Sativex in the EU in the second quarter as an adjunctive therapy for patients with spasticity due to multiple sclerosis who have achieved inadequate relief with existing therapies after the success of a pivotal Phase III trial.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.